Jazz wins first-line Ziihera approval as HERIZON-GEA-01 resets the HER2 treatment benchmark
FDA has approved two Ziihera-based first-line regimens in HER2-positive advanced gastroesophageal adenocarcinoma after the Tevimbra combination improved median overall survival from 19.2 to 26.4 months.
